Global Celecoxib API Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Celecoxib API Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Celecoxib API refers to the active pharmaceutical ingredient (API) of the drug Celecoxib, which is a non-steroidal anti-inflammatory drug (NSAID) used to relieve pain, inflammation, and stiffness caused by conditions such as osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. The Celecoxib API is the chemical compound responsible for the therapeutic effects of the drug. It is a selective cyclooxygenase-2 (COX-2) inhibitor, which means it works by blocking the production of prostaglandins, which are chemicals produced by the body in response to injury or inflammation. By reducing the production of prostaglandins, Celecoxib can help relieve pain, reduce inflammation, and improve joint mobility. The Celecoxib API is typically manufactured by pharmaceutical companies in accordance with strict quality control standards to ensure its purity, potency, and safety. It is then used to produce finished dosage forms of Celecoxib, such as tablets or capsules, which are prescribed by healthcare professionals to treat various inflammatory conditions.
Celecoxib API report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Celecoxib API market is projected to reach US$ 82 million in 2034, increasing from US$ 56 million in 2022, with the CAGR of 4.9% during the period of 2024 to 2034. Demand from Pharmaceutical and Laboratory are the major drivers for the industry.
Global key players of celecoxib API include Pfizer, Jiangxi Synergy, ScinoPharm, Jiangsu Hengrui Medicine, Jiangsu Chiatai Qingjiang, etc. The top five players hold a share over 73%. Asia Pacific is the largest market, has a share about 43%, followed by North America and Europe, with share 28% and 25%, separately.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Celecoxib API market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Pfizer
Teva Pharmaceuticals
Viatris(Mylan)
ScinoPharm
Jiangxi Synergy
Jiangsu Hengrui Medicine
Jiangsu Chiatai Qingjiang
Hisun Pharmaceutical Nantong
Aurobindo Pharma
Punjab Chemicals
Segment by Type
Standard grade Celecoxib API
Micronized Celecoxib API
Pharmaceutical
Laboratory
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Celecoxib API market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Celecoxib API, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Celecoxib API industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Celecoxib API in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Celecoxib API introduction, etc. Celecoxib API Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Celecoxib API market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Celecoxib API report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Celecoxib API market is projected to reach US$ 82 million in 2034, increasing from US$ 56 million in 2022, with the CAGR of 4.9% during the period of 2024 to 2034. Demand from Pharmaceutical and Laboratory are the major drivers for the industry.
Global key players of celecoxib API include Pfizer, Jiangxi Synergy, ScinoPharm, Jiangsu Hengrui Medicine, Jiangsu Chiatai Qingjiang, etc. The top five players hold a share over 73%. Asia Pacific is the largest market, has a share about 43%, followed by North America and Europe, with share 28% and 25%, separately.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Celecoxib API market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Pfizer
Teva Pharmaceuticals
Viatris(Mylan)
ScinoPharm
Jiangxi Synergy
Jiangsu Hengrui Medicine
Jiangsu Chiatai Qingjiang
Hisun Pharmaceutical Nantong
Aurobindo Pharma
Punjab Chemicals
Segment by Type
Standard grade Celecoxib API
Micronized Celecoxib API
Segment by Application
Pharmaceutical
Laboratory
Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Celecoxib API market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Celecoxib API, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Celecoxib API industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Celecoxib API in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Celecoxib API introduction, etc. Celecoxib API Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Celecoxib API market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.